Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keep up to date on new and emerging diagnostic tests, testing trends and opportunities, and disruptive technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
So far, 2017 is proving to be a good year for fundraising and investment in the broad health care industry, according to report by…
By Lâle White bio
As XIFIN predicted, the PAMA reporting exercise has resulted in significant proposed laboratory fee cuts. In fact…
From - Diagnostic Testing & Emerging Technologies
Routine annual tuberculosis (TB) screening of health care workers is no longer cost effective, according to a study published May 17 in BMC Medicine. The incidence of…
From - Diagnostic Testing & Emerging Technologies
Molecular diagnostics firm Curetis (Germany) specializes in solutions to rapidly diagnose and profile antibiotic resistance for severe infections in hospitalized…
By Mike O'Brien bio
Lots of ADA Facility Lawsuits in Utah: Here is an interesting legal news update from my partner Mike Judd: Title III of the Americans with Disabilities Act (ADA) requires places of…
From - Diagnostic Testing & Emerging Technologies
The American Society of Clinical Oncology (ASCO) published updated practice guidelines Aug. 14 in the Journal of Clinical Oncology regarding the use of…
From - G2 Blog
It is a recurrent challenge for human resource professionals: Determining whether an employee is exempt from the overtime requirements of the…
From - Diagnostic Testing & Emerging Technologies
The power of celebrity impacts health decisions and drives testing decisions beyond the "Angelina Jolie effect." A study published in the…